Introduction: Thromboembolic events are one of the major challenging complications following the total joint arthroplasty. Low molecular-weight heparin (LMWH) is used prevalently agent for thromboprophylaxis. The clexane is a well known brand of LMWH used all over the world including Iran. Recently, LMWH has been produced in Iran called enoxan. In current randomized study, we compared the efficacy of these two brands of LMWH in thromboprophylaxis after hip and knee arthroplasty.

Materials and methods: Between March to August 2014, there were 60 patients with primary hip or knee osteoarthritis underwent total joint arthroplasty in Akhtar hospital. The patients assigned randomly to one of the groups: enoxan and clexane. The agent was administered for 14 days after hip arthroplasty and  21 days after knee arthroplasty (40 mg daily). The patients suspected for deep venous thrombosis were examined using doppler ultrasound. The patients were followed for three months. Finally, the data were compared between two groups.

Results: There was no patient with thromboembolic events. Also, none of the patients developed surgical site hematoma.

Conclusion: Enoxan is an efficient and safe agent for thromboprophylaxis after hip and knee arthroplasty. Since enoxan is produced in Iran,  thromboprophylaxis using this agent can be associated with substantial cost benefit. However, more large studies are required to confirm the efficacy and safety of enoxan.

Keywords: total knee arthroplasty, total hip arthroplasty, Low molecular-weight heparin, thromboprophylaxis